32.6 C
Vientiane
Sunday, August 24, 2025
spot_img
Home Blog Page 160

Silicon Motion Showcases MonTitan™ SM8366 in Core to Edge AI Server Applications at FMS 2025

Company Also Demonstrates Full Spectrum of AI Storage Solutions for PCs, Gaming, Edge, Robotics, and Automotive

TAIPEI and MILPITAS, Calif., Aug. 6, 2025 /PRNewswire/ — Silicon Motion Technology Corporation (NasdaqGS: SIMO) (“Silicon Motion”), a global leader in designing and marketing NAND flash controllers for solid-state storage devices, today announced it will showcase its MonTitan™ SM8366 PCIe Gen5 SSD controller solutions, demonstrated using the VAST Data Ceres V2 AI Storage platform and Aetina NVIDIA MGX™ server, at FMS (the Future of Memory and Storage) 2025 in Santa Clara, California, taking place August 5–7 in at booth #315. MonTitan™, together with other advanced storage solutions optimized for AI applications, underscores Silicon Motion’s commitment to delivering next-generation scalability and performance for data-intensive workloads

Silicon Motion showcases MonTitan™ SM8366 controller based Unigen Cheetah SSDs on the VAST Data Ceres V2 platform
Silicon Motion showcases MonTitan™ SM8366 controller based Unigen Cheetah SSDs on the VAST Data Ceres V2 platform

Silicon Motion is collaborating with Unigen to demonstrate its Cheetah High Capacity 128TB QLC E1.L SSD and Cheetah 3.2TB SLC U.2 SSD powered by Silicon Motion’s SM8366 to showcase an efficient and cost-effective storage solution by using VAST Data Ceres V2 Dbox platform. By leveraging NVIDIA BlueField-3 DPUs to accelerate networking and compute combined with its compact 1U form factor, CERES V2 delivers exceptional density for mission-critical AI deployments that demand scalability and throughput. 

“We are pleased to work with Silicon Motion’s MonTitan™ based SSDs that support the Ceres V2 architecture to meet the performance and density demands of AI and data-intensive workloads,” said Avery Pham, VP of Strategic Operations, at VAST Data. “VAST is a Software Data platform utilizing bleeding edge hardware to enable software solutions. This demo illustrates how integrating powerful SSD technology with a disaggregated storage architecture like Ceres2 can help enterprises scale AI infrastructure more efficiently and intelligently.”

Silicon Motion has also teamed up with Innodisk 5TS-P on an 8TB E1.S MonTitan™ based SSD by using Aetina’s AEX-2UAI, high performance, short-depth edge server built on NVIDIA’s MGX™ module design. This edge server brings powerful AI computing capabilities to edge environments and is particularly suitable for use cases demanding high performance in space-constrained settings.  

“The integration of MonTitan™ based 5TS-P SSDs into our AEX-2UAI edge server reflects a shared vision to support powerful AI computing in compact, real-world deployments,” said CC Wu, GM of Embedded Flash Division at Innodisk. “By combining high-density flash storage with MGX-based computing, we’re expediting edge AI systems to perform faster and smarter in space optimized environments.”

“Our MonTitan™ platform is purpose-built to address the extreme demands of AI server storage,” said Alex Chou, Senior Vice President of Enterprise Storage and Display Interface Solutions Business at Silicon Motion. “Our collaborations with customers and module maker partners highlight our ability to deliver leading AI SSD solutions.  We are thrilled to be part of the Core to Edge AI Ecosystems with VAST Data, Aetina and our other partners to deliver storage solutions that meet the ultra-high capacity and performance requirements of the next generation of AI applications for data centers and enterprise storage.”

In addition to the AI server storage demo, Silicon Motion will highlight its broad portfolio of storage solutions designed for a wide range of AI-driven applications—from all-in-one Edge AI and AI PCs to gaming consoles, smartphones, robotics, and automotive systems. This includes PCIe Gen5 SSD, USB4, SD Express, UFS, and eMMC controllers, along with Ferri embedded storage, underscoring the company’s expertise in delivering scalable, high-efficiency storage across diverse AI platforms.

Silicon Motion representatives will also be presenting at FMS keynotes and forums. For further information, please visit: https://www.siliconmotion.com/events/2025FMS/

About Silicon Motion:

We are the global leader in supplying NAND flash controllers for solid state storage devices. We supply more SSD controllers than any other company in the world for servers, PCs and other client devices and are the leading merchant supplier of eMMC and UFS embedded storage controllers used in smartphones, IoT devices and other applications. We also supply customized high-performance hyperscale data center and specialized industrial and automotive SSD solutions. Our customers include most of the NAND flash vendors, storage device module makers and leading OEMs. For further information on Silicon Motion, visit us at www.siliconmotion.com.

Silicon Motion showcases MonTitan™ SM8366 controller based Innodisk 5TS-P SSDs with Aetina’s MGX-based AEX-2UAI edge server
Silicon Motion showcases MonTitan™ SM8366 controller based Innodisk 5TS-P SSDs with Aetina’s MGX-based AEX-2UAI edge server

WuXi AppTec Named Constituent of the FTSE4Good Index Series for Third Consecutive Year

SHANGHAI, Aug. 6, 2025 /PRNewswire/ — WuXi AppTec, a global company that provides a broad portfolio of R&D and manufacturing services to enable companies in the pharmaceutical and life science industries, today announced its inclusion in the FTSE4Good Index Series for the third consecutive year. This recognition underscores the Company’s ongoing commitment to sustainable development and its efforts to build a healthier, more sustainable world.

Created by the global index and data provider FTSE Russell, the FTSE4Good Index Series is designed to measure the performance of companies demonstrating specific Environmental, Social and Governance (ESG) practices. Inclusion in the index is based on meeting specific ESG criteria. In the most-recent assessment cycle, WuXi AppTec achieved the highest score of 5 points in Corporate Governance, Anti-Corruption, and Labor Standards, reflecting the Company’s exemplary performance in sustainable management.

“We are honored to be recognized once again by FTSE Russell as a constituent of the FTSE4Good Index Series. This acknowledgement affirms the capital markets’ confidence in WuXi AppTec’s sustainable management practices,” said Dr. Steve Yang, Co-CEO of WuXi AppTec and Chairman of WuXi AppTec’s ESG Committee. “We remain committed to advancing our ESG initiatives while supporting our customers in bringing innovative new therapies to patients worldwide.”

As an enabler of innovation, a trusted partner, and a contributor to the global pharmaceutical and life sciences industry, WuXi AppTec strategically integrates sustainability like most of the customers into its global operations. The company’s ESG leadership has been recognized by several prestigious organizations: WuXi AppTec has received the MSCI ESG Leadership Rating for five consecutive years, has been included in the Dow Jones Sustainability Index (DJSI) for four consecutive years, and has earned an A- Leadership rating in the CDP Climate Change assessment for three consecutive years. Additionally, the Company has been recognized as an Industry and Regional ESG Top-Rated Company by Morningstar Sustainalytics, received its first MSCI ESG AAA rating, achieved an A Leadership rating in the CDP Water Security assessment, and was awarded a Gold Medal in the EcoVadis sustainability rating.

Furthering its sustainability commitments, WuXi AppTec has received Science Based Targets initiative (SBTi) validation for its near-term emissions reduction targets. The Company is also a participant in the United Nations Global Compact (UNGC), supporting its ten principles, and serves as a supplier partner to the Pharmaceutical Supply Chain Initiative (PSCI).

About WuXi AppTec

WuXi AppTec is a trusted partner and contributor to the pharmaceutical and life sciences industries, providing R&D and manufacturing services that help advance healthcare innovation. With operations across Asia, Europe, and North America, we offer integrated, end-to-end services through our unique CRDMO (Contract Research, Development, and Manufacturing Organization) platform. We are privileged to work alongside nearly 6,000 partners across 30+ countries, supporting their efforts to bring breakthrough treatments to patients. Guided by our vision that every drug can be made and every disease can be treated, we are committed to advancing breakthroughs for patients—one collaboration at a time. Learn more at www.wuxiapptec.com.

U.S., Japan, and Taiwan Experts Gather at NUWA Forum — Over 200 Reproductive Specialists Explore the Future of Integrated Fertility Technology

Is Increased Use of PGT-A Always Better? Experts Call for Evidence-Based Use of Mosaic Embryos
Choosing the Right PGT-A Platform: NUWA Fertility and Global Experts Unite to Advance IVF Success

TAIPEI, Aug. 6, 2025 /PRNewswire/ — Preimplantation Genetic Testing for Aneuploidy (PGT-A), a screening method used during IVF to assess embryo chromosomal health, has gained widespread adoption in reproductive medicine worldwide. Yet the accuracy of various PGT-A platforms and their true clinical value remain points of ongoing debate. To dive deeper into the science behind PGT-A and explore the latest validated technologies, NUWA Fertility partnered with the Institute of Biotechnology at National Taiwan University to host its annual Reproductive Medicine Forum on August 3. The event welcomed over 200 fertility professionals and representatives from more than 65 reproductive centers, drawing international experts from the U.S. and Japan for a day of lively discussion and data-driven insights.

NUWA brought together over 200 reproductive medicine professionals from more than 65 IVF centers for a landmark forum on the future of fertility.
NUWA brought together over 200 reproductive medicine professionals from more than 65 IVF centers for a landmark forum on the future of fertility.

New Global Research Questions Conventional Use of Mosaic Embryos

One of the forum’s most anticipated speakers, Dr. Chaim Jalas – CEO and Director of Research and Development at U.S.-based Juno Genetics – presented findings from two prospective studies spanning the U.S. and Europe, with a combined dataset of 15,000 embryo samples. The research showed that when PGT-A is performed using the most advanced, clinically validated platforms, mosaic embryos (those containing both normal and abnormal cells) do not necessarily need to be discarded. By accurately identifying and excluding only embryos with chromosomal abnormalities, clinics can improve live birth rates, reduce embryo waste, and lower the risk of miscarriage.

Dr. Chi-Hong Liu, the Chief Medical Advisor at NUWA Fertility and convener of the forum, emphasized that PGT-A can only deliver meaningful results when the platform is backed by solid evidence and high diagnostic accuracy. He noted that many currently used platforms lack sufficient clinical validation when it comes to identifying mosaic embryos. “Many embryos classified as mosaic still have the potential to implant and result in healthy live births,” said Dr. Liu. “If we discard them based on imprecise technology, we’re not only limiting patients’ chances but possibly wasting embryos with real potential.”

AI-Powered Embryo Selection: Precision without Harm

Mr. Takahashi, a senior embryologist from Japan’s renowned Kato Ladies Clinic, shared advancements in embryo assessment using AI combined with time-lapse imaging technology. This non-invasive method continuously monitors embryo development and uses algorithmic scoring to improve selection accuracy – particularly useful for patients with a limited number of eggs or who should avoid repeated ovarian stimulation. The approach has significantly improved success rates for single embryo transfer, a strategy aimed at reducing the risks of multiple pregnancies.

Behind Every IVF Success: A Seamless Teamwork Between Lab and Clinic

Dr. Shang-Gwo Horng, the Director of NUWA Fertility Center, offered clinical strategies for gentle yet effective ovarian stimulation and medication protocols that support embryo quality. And Dr. Chung-Hao Lu, a leading researcher and embryologist, discussed best practices for helping patients improve embryo outcomes through lifestyle and treatment. He emphasized that even the best PGT-A platform can fail if the biopsy timing, technique, or sample handling are subpar. “Close coordination between physicians and embryologists is absolutely essential to maximize IVF success,” said Dr. Lu.

NUWA Forum: Advancing Fertility Through Evidence-Based Collaboration

Dr. Chi-Hong Liu concluded by reaffirming NUWA’s mission to drive innovation through open knowledge-sharing and scientific rigor. “By building a better-validated, more reliable PGT-A platform, we can help patients increase their chances of success while reducing unnecessary stress and resource loss.”

Now in its third consecutive year, NUWA Fertility’s Reproductive Medical Forum continues to be a vital platform for pushing boundaries in fertility care. Dr. Liu added that NUWA will remain committed to integrating clinical decision-making, lab excellence, and global collaboration to elevate Taiwan’s reproductive medicine on the international stage.

Get to know NUWA: https://www.nuwacare.com/en

Bracco Imaging Receives Regulatory Approval in China for SonoVue® in the Assessment of Fallopian Tube Patency

New indication of SonoVue® supports non-invasive assessment of female infertility through contrast-enhanced ultrasound in China

MILAN, Aug. 6, 2025 /PRNewswire/ — Bracco Imaging, a global leader in diagnostic imaging, today announced that its ultrasound contrast agent SonoVue® has been approved by the China’s National Medical Products Administration (NMPA) for use in hysterosalpingo contrast sonography (HyCoSy).

HyCoSy is a contrast-enhanced ultrasound (CEUS) procedure that helps identifying potential causes of female infertility related to blockage of the fallopian tubes or uterine abnormalities with a high level of diagnostic accuracy (1,2). Fallopian tube conditions, such as blockages, scarring, or other damage, are a leading cause of infertility, contributing to approximately 25–35 percent of cases of infertility among women in China (3).

This regulatory approval represents an important milestone in the management of infertility because, unlike laparoscopic assessment of tubal patency with use of a dye, HyCoSy is a non-invasive procedure, and, unlike traditional X-ray hysterosalpingography, HyCosy does not expose to radiation the genital tract of women in their reproductive years (4-6).

“The NMPA approval of SonoVue® use with HyCoSy marks an important step in expanding access to non-invasive, radiation-free detection of tubal issues and uterine problems that often cause infertility in women,” said Alberto Spinazzi, Chief Medical and Regulatory Officer, Bracco Group. “We strive to provide healthcare professionals in China with solutions that advance standards of care, reflecting our commitment to advancing diagnostic precision and improving the patient experience through contrast-enhanced ultrasound.”

“We are proud to support China’s healthcare priorities through solutions like SonoVue® that may help address important diagnostic needs,” said Valtero Canepa, Head of APAC, Bracco Imaging. “This new indication advances Bracco’s role in delivering meaningful innovation in support of the Healthy China 2030 initiative, which prioritizes earlier detection, clinical precision, and broader access to reproductive health services.”

The high diagnostic performance of HyCoSy with SonoVue® has been confirmed by a recent systematic review and meta-analysis of 24 clinical studies (total of 1358 women with infertility and 2661 fallopian tubes). Using laparoscopic chromotubation dye test as the standard of truth for the assessment of fallopian tube patency, the pooled estimates of sensitivity, specificity, and accuracy of HyCoSy with SonoVue® were 93%, 90%, and 96%, respectively (1). 

Backed by over 20 years of clinical use, SonoVue® is the ultrasound contrast agent with the largest number of approved indications in the largest number of countries worldwide. The newly approved HyCoSy indication reinforces Bracco Imaging’s commitment to expanding non-invasive, high-quality diagnostic tools aligned with evolving clinical standards and national health objectives in China and beyond.

  1. Qu E, Zhang M, Ju J, Chen Y, Lin X, Zhang X. Is Hysterosalpingo-Contrast Sonography (HyCoSy) Using Sulfur Hexafluoride Microbubbles (SonoVue) Sufficient for the Assessment of Fallopian Tube Patency? A Systematic Review and Meta-Analysis. J Ultrasound Med 2023; 42:7-15
  2. Wang T, Dong T, Nie F. Clinical applications, advances, and future directions in hysterosalpingography. Front Med 2025; 12:1537506
  3. Reproductive Health Branch of Chinese Preventive Medicine Association. Chinese Expert Consensus on Holistic Management of Tubal Factor Infertility (2023 edition) [J]. Chinese Journal of Practical Gynecology and Obstetrics 2023; 39:318-324
  4. Roy KK, Gajapathy SR, Rai R, Zangmo R, Das A, Singhal S. Assessment of Tubal Patency with Selective Chromopertubation at Office Hysteroscopy versus Modified Minilaparoscopy in Infertile Women. Gynecol Minim Invasive Ther 2021; 10:159-165
  5. Perisinakis K, Damilakis J, Grammatikakis J, Theocharopoulos N, Gourtsoyiannis N. Radiogenic risks from hysterosalpingography. Eur Radiol 2003; 13:1522-1528
  6. Sulieman A, Theodorou K, Vlychou M, Topaltzikis T, Roundas C, Fezoulidis I, Kappas C. Radiation dose optimisation and risk estimation to patients and staff during hysterosalpingography. Radiat Prot Dosimetry 2008;128:217-226

For additional information about Bracco’s products, and for full prescribing information, please visit https://www.bracco.com/.

About Bracco Imaging
Bracco Imaging S.p.A. (“Bracco Imaging”), part of the Bracco Group, is an innovative world leader delivering end-to-end products and solutions through its comprehensive portfolio across diagnostic imaging modalities. Headquartered in Milan, Italy, Bracco Imaging’s purpose is to improve people’s lives by shaping the future of prevention and precision diagnostic imaging. The Bracco Imaging portfolio includes products and solutions for all key diagnostic imaging modalities: X-ray imaging, magnetic resonance imaging (MRI), Contrast Enhanced Ultrasound (CEUS), and Nuclear Medicine through radioactive tracers and novel PET imaging agents. Bracco Imaging has 3,800 employees and operates in more than 100 markets globally. Bracco Imaging has a well skilled and innovative Research and Development (R&D) organization with an efficient process-oriented approach and track record in the diagnostic imaging industry. Discover Bracco at https://www.bracco.com/.

Media Contacts:

Bracco Press Contact:
Carolina Bargoni
Bracco Imaging, Communications Director
Carolina.bargoni@bracco.com
+39 347 5397738

Calm Stores, Clear Sites: New Research Highlights How Seniors are Redefining Retail Expectations

SYDNEY, Aug. 6, 2025 /PRNewswire/ — While many Australians are adjusting their spending in response to rising cost-of-living, new research from Manhattan Associates Inc. (NASDAQ: MANH) reveals that older Australians continue to play a significant role in discretionary retail. Backed by financial stability and a clear preference for personalised, supportive in-store experiences, over-55s represent a key growth opportunity for retailers who are willing to meet them on their terms.

Photo Credit: Adobe Stock
Photo Credit: Adobe Stock

Shoppers aged 55+ are spending, but their expectations are high

According to the research, 68% of mature-aged shoppers reported either no impact or improved confidence in their personal finances, despite ongoing interest rate pressures. Notably, 64% also said that special offers and promotions influence their spending decisions in-store, demonstrating a willingness to engage, provided the experience is worthwhile.

“These shoppers are among the most financially secure and active in the retail space,” said Raghav Sibal, Vice President of APAC at Manhattan Associates. “But they’re also more discerning. They’re not shopping just for products, they’re shopping for a comfortable, helpful and human experience.”

The research revealed that older Australians value a quieter, calmer in-store environment. Two-thirds (66%) of shoppers aged 55 and over said they would prefer retailers to turn down in-store music or avoid it altogether, with one in four (24%) reporting they have actively avoided stores that feel too loud or chaotic.

In addition to creating the right environment, staffing also plays a critical role in shaping the in-store experience for senior shoppers. Only 26% of over-55s said they like to shop entirely independently. Most prefer some level of support, particularly when engaging with new technologies or unfamiliar products. Encouragingly for retailers, 41% of mature-aged consumers said they would shop in-store more often if there were more staff available to assist.

“Retailers sometimes assume that mature-age shoppers want to be left alone, but the data tells a different story. This group values human connection, reassurance, and calm environments. Creating in-store experiences that reduce sensory overload and provide access to well-informed, available staff will go a long way in driving loyalty and repeat visits,” said Sibal.

Technology should support, not replace, human interaction

Senior shoppers are not averse to using technology instore with 73% of shoppers being comfortable using self-checkouts and similar solutions. However, of those surveyed 40% of shoppers said that they usually prefer or require some assistance when using these tools.

“Mature-aged Australian shoppers are often willing to try and use instore technologies to speed up their retail experience, however they often need to be supported by knowledgeable staff in-store,” said Sibal. “It’s that personal interaction that makes the difference, someone who can answer questions or offer guidance.”

Older Australians are increasingly confident online, but want reassurance and clarity

Contrary to common assumptions, senior shoppers are far from digital holdouts. In fact, 65% of Australians aged 55 and over now say they are more likely to shop online due to factors like convenience, better access to deals and broader product selection available through digital channels.

This growing digital fluency is also reflected in user experience, with 57% of mature-age shoppers reporting they rarely or never encounter issues when shopping online. Only 10% say they frequently run into problems, highlighting a general comfort with digital retail.

However, attracting and retaining these shoppers requires retailers to understand the needs of older shoppers. A third (32%) say they would be encouraged to shop online more often if retailers provided clear reassurance around website security. Meanwhile, 28% want more detailed product descriptions and customer reviews to support informed decision-making and 20% said easier-to-navigate websites would increase their likelihood to purchase.

“We’re seeing a generational shift in how older Australians interact with digital commerce. This group is highly pragmatic. They’re not just looking for tech-savvy interfaces, rather they want clarity, trust and a sense of control. Retailers that invest in intuitive website design, transparent product information and strong cybersecurity messaging are more likely to win their confidence and their business,” concluded Sibal.

For more information, please visit www.manh.com.au

Methodology:

Manhattan Associates surveyed 500 Australian consumers over the age of 55.

ABOUT MANHATTAN ASSOCIATES
Manhattan Associates is a global technology leader in supply chain and omnichannel commerce. We unite information across the enterprise, converging front-end sales with back-end supply chain execution. Our software, platform technology and unmatched experience help drive both top-line growth and bottom-line profitability for our customers.

Manhattan Associates designs, builds, and delivers leading edge cloud and on-premises solutions so that across the store, through your network or from your fulfillment centre, you are ready to reap the rewards of the omnichannel marketplace. For more information, please visit www.manh.com 

Japanese Workforce Lags APAC in Flexibility, ESG Priorities, and Ambition, But Change Is Underway, Reeracoen × Rakuten Insight Study Finds

TOKYO, Aug. 6, 2025 /PRNewswire/ — Japan’s workforce is undergoing slow but significant transformation, even as it ranks the lowest across Asia-Pacific in ambition, mobility, and values-driven employment decisions. A newly released white paper by recruitment firm Reeracoen and research agency Rakuten Insight Global highlights how cultural norms around stability and tradition are giving way to quiet shifts in upskilling and flexibility.

The Reeracoen × Rakuten Insight APAC Workforce Whitepaper 2025, which surveyed over 12,000 professionals across 12 Asia-Pacific markets, reveals that Japan trails the region in several key workforce indicators. Only 24% of Japanese respondents strongly aspire to leadership roles, only 48% say ESG factors influence their employment decisions, and hybrid work adoption remains low at 33%.

“This report highlights a pivotal truth: the future of work in Japan depends on how well businesses can balance tradition with change,” said Kenji Naito, Group CEO of Reeracoen. “While the data shows Japan ranks lowest in ambition, mobility, and ESG alignment, it also reveals an opportunity. Organisations that respond to these shifts through flexibility, purpose, and skills development will lead the next chapter of Japan’s growth.”

Mr. Kenji Naito, Group Chief Executive Officer, Reeracoen Group
Mr. Kenji Naito, Group Chief Executive Officer, Reeracoen Group

Key Findings from Japan:

  • Conservative Career Ambitions: Only 24% of Japanese workers strongly aspire to leadership roles, well below the APAC average of 37%.
  • Limited ESG Influence: Only 48% of respondents evaluate CSR or ESG commitments when choosing an employer. This is the lowest score in the region.
  • Slow Progress on Flexibility: While 65% of respondents say flexibility is important, only 33% currently have access to a hybrid work arrangement.
  • Reluctance to Relocate: Japan has the lowest rates of openness to relocation, with only 9% of respondents open to moving overseas for work.
  • Upskilling Gathers Momentum: There are encouraging signs that Japanese workers are taking more ownership over their career development. One in three workers (33%) are now pursuing skills development independently, primarily through certifications and online platforms.
  • Conservative Salary Expectations: Only 13% expect a pay rise of more than 10% this year, compared to 21% regionally.

As Japan’s demographic challenges intensify and global competition for skilled talent increases, the need to adapt is becoming more urgent. Lifetime employment and seniority remain strong anchors; however, the data suggests that quiet and meaningful changes in areas such as hybrid work and digital learning are already underway. Employers that enhance their policies around flexibility, ESG, and upskilling will be better positioned to attract younger, more globally minded professionals.

Japan’s labour market is quietly but steadily evolving,” said Kosuke Soejima, Managing Director of Reeracoen Japan. “As global trends accelerate, our clients are recognising that attracting and retaining talent requires more than stability. It demands purpose, trust, and flexible, human-centric work models.”

Mr. Kosuke Soejima, Managing Director, Reeracoen Japan
Mr. Kosuke Soejima, Managing Director, Reeracoen Japan

About the Study

 The whitepaper synthesises insights from over 12,000 respondents across the APAC region, including Japan. It provides both regional analysis and market-specific breakdowns to support workforce benchmarking and strategic planning.

About Reeracoen

Reeracoen is an award-winning leader in Asia’s recruitment landscape, connecting top-tier talent with forward-thinking organisations across the region. With nine offices across six major Asian countries, we combine deep local networks with cross-border hiring expertise to help businesses grow faster and stronger.

Our excellence has been recognised with recent awards such as:

  • Best Recruitment & Talent Acquisition Agency 2025
  • Best International Recruitment & Talent Acquisition Agency 2024
  • Best Executive Recruitment Agency 2024

We uphold the highest standards of professionalism and service quality, providing innovative and trusted recruitment solutions to help businesses and candidates succeed in an evolving digital economy. For more information, visit https://www.reeracoen.sg and follow us on LinkedIn for the latest updates and insights.

About Rakuten Insight Global, Inc.

Rakuten Insight Global, Inc. (“Rakuten Insight”) is a wholly-owned online market research subsidiary of Rakuten Group, Inc., a global leader in internet services, headquartered in Tokyo. Rakuten Insight was established in 1997 as AIP Corporation and became part of the Rakuten Group in 2014. Rakuten Insight possesses a research panel focusing on 12 major Asian markets & the US and a panel network covering 60 countries and regions. With offices in 11 countries and regions, Rakuten Insight provides market research for over 500 leading companies around the world. Rakuten Insight Singapore serves as an off-shore market research hub to drive business development and provide multi-lingual and multi-functional operational support for clients based across Southeast Asia. For more information, visit https://insight.rakuten.com/  and follow us on social media.

 

 

Medtronic to announce financial results for its first quarter of fiscal year 2026

GALWAY, Ireland, Aug. 6, 2025 /PRNewswire/ — Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today announced that it will report financial results on Tuesday, August 19, 2025, for its first quarter of fiscal year 2026, which ended on Friday, July 25, 2025,

Looking ahead, Medtronic plans to report its fiscal year 2026 second, third, and fourth quarter results on Tuesday, November 18, 2025, February 17, 2026, and Wednesday, May 20, 2026, respectively. Confirmation and additional details will be provided closer to the specific event.

About Medtronic
Bold thinking. Bolder actions. We are Medtronic. Medtronic plc, headquartered in Galway, Ireland, is the leading global healthcare technology company that boldly attacks the most challenging health problems facing humanity by searching out and finding solutions. Our Mission — to alleviate pain, restore health, and extend life — unites a global team of 95,000+ passionate people across more than 150 countries. Our technologies and therapies treat 70 health conditions and include cardiac devices, surgical robotics, insulin pumps, surgical tools, patient monitoring systems, and more. Powered by our diverse knowledge, insatiable curiosity, and desire to help all those who need it, we deliver innovative technologies that transform the lives of two people every second, every hour, every day. Expect more from us as we empower insight-driven care, experiences that put people first, and better outcomes for our world. In everything we do, we are engineering the extraordinary. For more information on Medtronic (NYSE: MDT), visit www.Medtronic.com and follow Medtronic on LinkedIn.

Any forward-looking statements are subject to risks and uncertainties such as those described in Medtronic’s periodic reports on file with the Securities and Exchange Commission. Actual results may differ materially from anticipated results.

Contacts:
Erika Winkels
Public Relations
+1-763-526-8478

Ryan Weispfenning
Investor Relations
+1-763-505-4626

 

New revolutionary brain tech platform ‘ScreenIT’ puts smarter concussion care in reach

SYDNEY, Aug. 6, 2025 /PRNewswire/ — A revolutionary new brain health assessment platform, ScreenIT, has officially launched, marking a major step forward in how brain function is monitored, assessed, and optimised across sport, healthcare, and research sectors. Developed through a close partnership between Your Brain Health (YBH) and digital innovation studio Miroma Project Factory, ScreenIT unifies over 50 brain health assessment tools into a single, intelligent platform designed to support faster, more informed decision-making around concussion, performance, and long-term brain care.

ScreenIT provides real-time brain health insights giving athletes, clinicians, and researchers the tools to manage concussion and performance with confidence.
ScreenIT provides real-time brain health insights giving athletes, clinicians, and researchers the tools to manage concussion and performance with confidence.

Miroma Project Factory, specialists in creating high-impact digital solutions for health, consumer, broadcast and government sectors, collaborated with YBH’s visionary team, led by CEO Gregory Rosenbauer who states:

 “ScreenIT is more than an assessment tool – it’s an intelligent ecosystem that empowers clinicians, athletes, researchers, and communities to make better decisions, faster (about your brain health). From concept to launch, this has been a true collaboration driven by innovation, care, and a shared mission to foster healthier brains “

ScreenIT addresses a major gap in the market. Historically, brain health assessments have been fragmented and inconsistent. ScreenIT changes that by offering an integrated, real-time picture of brain function, pulling from a library of validated technologies and assessments. From elite athletes in the top-tier UK football competitions and Formula 1 to community clinics and research labs, ScreenIT delivers actionable insights when and where they’re needed most.

“Because every brain deserves better decisions, faster care and a healthier future. With Miroma Project Factory’s expertise, we’ve been able to realise a vision for a platform that not only improves concussion management but opens new pathways in talent identification, performance optimisation, and neurological research. Together, we’re building the foundation for a global brain health ecosystem to transform a bold idea into a globally scalable platform set to redefine brain health management.” said Gregory Rosenbauer, CEO and Co-Founder of Your Brain Health.

Backed by leaders in global sports medicine, including Professor Jon Patricios, founder of Sports Concussion South Africa and consultant to World Rugby, and Professor Mike Loosemore, former Chief Medical Officer of the UK Olympic Team, ScreenIT is positioned to become the gold standard in brain health technology.

Prof. Mike Loosemore MBE said, “Brain health is one of the most important yet overlooked frontiers in medicine. ScreenIT represents an opportunity to change that. By making brain function measurable, trackable and actionable, clinicians, athletes, and researchers are able to make better decisions that lead to healthier brains and better lives.”

ScreenIT is now available for selected partners and is being rapidly adopted across major sporting organisations and research institutions, with future plans including:

  • Building a globally significant brain health data lake
  • Integrating AI-driven predictive and personalised brain insights
  • Achieving regulatory approval as the first-ever diagnostic tool for concussion and brain health management

Availability and Use

ScreenIT is now available for clinics within Australia and the UK market. Learn more about Your Brain Health and the ScreenIT platform here:

Your Brain Health: Fostering A World Of Healthier Brains

About Miroma Project Factory

Miroma Project Factory is a multi-award-winning digital production and development house specializing in creating innovative, interactive digital products across web, mobile, social media, and games platforms. With a deep expertise in health tech, sports tech, and gamification for behavior change, Miroma Project Factory partners with visionaries to bring impactful ideas to life. Visit https://www.theprojectfactory.com/ for more information.

To learn more about the creation of ScreenIT, explore our interview with Gregory Rosenbauer, CEO and Co‑Founder of Your Brain Health, in the Tech Founder Interview Series. For further details about the platform, visit the MPF ScreenIT case study https://www.theprojectfactory.com/projects/ybh 

About Your Brain Health (YBH)

Your Brain Health is a medical health and biotech company dedicated to improving brain health outcomes through innovative technology, education, and data-driven solutions. Led by a team of experts across sports medicine, neuroscience, and digital health, YBH’s mission is to foster a world of healthier brains through smarter care and faster decisions. 

For media inquiries, interviews, or partnership opportunities, please contact:

Miroma Project Factory
info@theprojectfactory.com

Gregory Rosenbauer
Chief Executive Officer
Your Brain Health
+61 4 1788 9263
greg.rosenbauer@yourbrainhealth.io